Oxford Immunotec Global PLC (NASDAQ:OXFD) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $16.17 and traded as low as $14.42. Oxford Immunotec Global shares last traded at $14.46, with a volume of 93,865 shares.

OXFD has been the topic of several analyst reports. TheStreet upgraded Oxford Immunotec Global from a “d+” rating to a “c-” rating in a report on Tuesday, November 19th. Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th. Finally, BidaskClub lowered Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $19.67.

The company has a current ratio of 13.24, a quick ratio of 12.65 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average price of $16.04 and a 200 day moving average price of $15.47. The firm has a market cap of $384.80 million, a PE ratio of 2.81 and a beta of 0.42.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC raised its holdings in Oxford Immunotec Global by 218.9% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,805 shares of the company’s stock valued at $29,000 after buying an additional 1,239 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in Oxford Immunotec Global in the 4th quarter valued at about $78,000. Royce & Associates LP purchased a new stake in Oxford Immunotec Global in the 4th quarter valued at about $86,000. Macquarie Group Ltd. purchased a new stake in Oxford Immunotec Global in the 2nd quarter valued at about $108,000. Finally, Cornerstone Investment Partners LLC purchased a new stake in Oxford Immunotec Global in the 4th quarter valued at about $175,000. Institutional investors and hedge funds own 93.67% of the company’s stock.

Oxford Immunotec Global Company Profile (NASDAQ:OXFD)

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Read More: What are municipal bonds?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.